Press Releases & Events 2017

Proceeds to be used to further develop Tessa’s advanced solid tumor immunotherapy pipeline. Funding round reinforces Tessa’s position as an emerging leader in cellular immunotherapy with the vision of bringing transformational change to cancer therapy.

Tessa Therapeutics, a clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for solid tumors, today announces the appointment of Mr. Desmond Lim as Chief Financial Officer.

Tessa Therapeutics (Tessa), a clinical stage biopharmaceutical company, today announced the appointment of Ms. Jennifer Butler as Chief Commercial Officer…

Tessa Therapeutics (Tessa) and the Parker Institute for Cancer Immunotherapy (Parker Institute) today announced the establishment of a multi-year strategic alliance to combine their capabilities to jointly advance research in the field of cancer immunotherapy…

Tessa Therapeutics (Tessa) presented biomarker data from its Phase II trial for its lead candidate TT10, Epstein-Barr virus specific autologous cytotoxic T lymphocyte (CTL) therapy targeting advanced nasopharyngeal carcinoma, at ASCO’s annual meeting, 2017…

Tessa Therapeutics, an immunotherapy company dedicated to revolutionizing the treatment of cancer, and Vyriad, an oncolytic virotherapy company using engineered viruses to destroy tumors and boost the antitumor immune response, today announced a collaboration that will enable Tessa and Vyriad to investigate T cell and oncolytic virus combination therapies…

Tessa Therapeutics, an immunotherapy company dedicated to revolutionizing the treatment of cancer, today announced the full acquisition of Euchloe Bio, a biotechnology company specializing in the development and commercialization of antibodies to treat cancer…

Tessa Therapeutics, an immunotherapy company dedicated to revolutionizing the treatment of cancer, today announced the formation of a joint immuno-oncology laboratory located in A*STAR’s Institute of Molecular and Cell Biology (IMCB)…